Objective:To analyze the clinical features and prognostic risk factors of female patients with acute myo‐cardial infarction (AMI) .Methods :From Apr 2011 to Oct 2014 ,a total of 97 female AMI patients treated in our hospital were enrolled as female group ,meanwhile 120 male AMI patients were regarded as control group (male group) .All patients received three‐month follow‐up after hospitalization .Baseline data ,clinical features and prog‐nosis were compared between two groups ,and prognostic risk factors of female patients were analyzed at the same time .Results:Compared with male group ,there were significant rise in percentages of cardio‐and cerebrovascular diseases ,diabetes mellitus and hyperlipidemia ,and significant reductions in red blood cell count ,hemoglobin level , and percentages of smoking&drinking history , digestive&urinary system diseases in female group , P<0.05 or <0.01. Compared with male group , there were significant rise in percentages of Killip class Ⅳ (14.17% vs . 24.74% ) ,three‐vessel coronary disease (3.33% vs . 12.37% ) , therapeutic rate of reperfusion (51.67% vs . 73.20% ) ,mortality (2.50% vs .9.28% ) and incidence of complications (19.17% vs .31.96% ) in female group ,P<0.05 all .Logistic analysis of regression showed that age ,previous cardio‐ and cerebrovascular diseases ,diabetes mellitus ,hyperlipidemia ,Killip cardiac function class and number of diseased coronary vessels were significantly cor‐related with prognosis (OR=0.176~4.931 , P<0.05 all) .Conclusion:Prognosis of female AMI patients is poorer than that of males .Prognosis is related to age ,cardio‐ and cerebrovascular diseases ,diabetes mellitus ,hyperlipi‐demia ,Killip cardiac function class ,and number of diseased coronary vessels .

Objective To explore the clinical effects of cardiac remote monitoring system in diagnosing arrhythmia. Methods All 410 patients with arrhythmia who were admitted and treated in our hospital from October 2010 to July 2013 were selected as research subjects. All patients were examined by routine 12 leads ECG,followed by cardiac re-mote monitoring system. Positive rates of the two examinations in the diagnosis of arrhythmia were compared and ana-lyzed. Results In 1d, 2d and 3d, positive rates of cardiac remote monitoring system in the diagnosis of sinus arrhyth-mia, atrial arrhythmia, atrioventricular junction arrhythmia, ventricular arrhythmia and heart block gradually in creased,and the differences of positive rates of the same disease in different days were statistically significant(P<0.05). Positive rates of cardiac remote monitoring system in the diagnosis of the above diseases in 1d were all significantly higher than those of routine 12 leads ECG, and the differences compared between the two methods were statistically significant (P<0.05). Conclusion Sensitivity of cardiac remote monitoring system in the diagnosis of arrhythmia is higher than that of routine 12 leads ECG. The system is able to reduce the rate of missed diagnosis of arrhythmia and is of great clinical value in reducing the rate of missed diagnosis of arrhythmia, which is worthy of clinical promotion and application.

BACKGROUND: High-grade serous ovarian cancer (HGSOC) is the biggest cause of gynecological cancer-related mortality because of its extremely metastatic nature. This study aimed to explore and evaluate the characteristics of candidate factors associated with the metastasis and progression of HGSOC. METHODS: Transcriptomic data of HGSOC patients' samples collected from primary tumors and matched omental metastatic tumors were obtained from three independent studies in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) were selected to evaluate the effects on the prognosis and progression of ovarian cancer using data from The Cancer Genome Atlas (TCGA) database. Hub genes' immune landscapes were estimated by the Tumor Immune Estimation Resource (TIMER) database. Finally, using 25 HGSOC patients' cancer tissues and 10 normal fallopian tube tissues, immunohistochemistry (IHC) was performed to quantify the expression levels of hub genes associated with International Federation of Gynecology and Obstetrics (FIGO) stages. RESULTS: Fourteen DEGs, ADIPOQ , ALPK2 , BARX1 , CD37 , CNR2 , COL5A3 , FABP4 , FAP , GPR68 , ITGBL1 , MOXD1 , PODNL1 , SFRP2 , and TRAF3IP3 , were upregulated in metastatic tumors in every database while CADPS , GATA4 , STAR , and TSPAN8 were downregulated. ALPK2 , FAP , SFRP2 , GATA4 , STAR , and TSPAN8 were selected as hub genes significantly associated with survival and recurrence. All hub genes were correlated with tumor microenvironment infiltration, especially cancer-associated fibroblasts and natural killer (NK) cells. Furthermore, the expression of FAP and SFRP2 was positively correlated with the International Federation of Gynecology and Obstetrics (FIGO) stage, and their increased protein expression levels in metastatic samples compared with primary tumor samples and normal tissues were confirmed by IHC ( P = 0.0002 and P = 0.0001, respectively). CONCLUSIONS This study describes screening for DEGs in HGSOC primary tumors and matched metastasis tumors using integrated bioinformatics analyses. We identified six hub genes that were correlated with the progression of HGSOC, particularly FAP and SFRP2 , which might provide effective targets to predict prognosis and provide novel insights into individual therapeutic strategies for HGSOC.
Humans ; Female ; Ovarian Neoplasms/pathology* ; Prognosis ; Gene Expression Profiling ; Transcriptome ; Tumor Microenvironment ; Receptors, G-Protein-Coupled/therapeutic use* ; Tetraspanins/genetics* ; Protein Kinases ; Integrin beta1/therapeutic use*

Entinostat plus exemestane in hormone receptor-positive (HR+) advanced breast cancer (ABC) previously showed encouraging outcomes. This multicenter phase 3 trial evaluated the efficacy and safety of entinostat plus exemestane in Chinese patients with HR + ABC that relapsed/progressed after ≥1 endocrine therapy. Patients were randomized (2:1) to oral exemestane 25 mg/day plus entinostat (n = 235) or placebo (n = 119) 5 mg/week in 28-day cycles. The primary endpoint was the independent radiographic committee (IRC)-assessed progression-free survival (PFS). The median age was 52 (range, 28-75) years and 222 (62.7%) patients were postmenopausal. CDK4/6 inhibitors and fulvestrant were previously used in 23 (6.5%) and 92 (26.0%) patients, respectively. The baseline characteristics were comparable between the entinostat and placebo groups. The median PFS was 6.32 (95% CI, 5.30-9.11) and 3.72 (95% CI, 1.91-5.49) months in the entinostat and placebo groups (HR, 0.76; 95% CI, 0.58-0.98; P = 0.046), respectively. Grade ≥3 adverse events (AEs) occurred in 154 (65.5%) patients in the entinostat group versus 23 (19.3%) in the placebo group, and the most common grade ≥3 treatment-related AEs were neutropenia [103 (43.8%)], thrombocytopenia [20 (8.5%)], and leucopenia [15 (6.4%)]. Entinostat plus exemestane significantly improved PFS compared with exemestane, with generally manageable toxicities in HR + ABC (ClinicalTrials.gov #NCT03538171).